Are prophylactic haematopoietic growth factors of value in the management of patients with aggressive non-Hodgkin's lymphoma?

British Journal of Cancer

Volumn 90, Issue 7, 2004, Pages 1302-1305

  Hackshaw, A ^a   Sweetenham, J ^b   Knight, A ^c  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF COLORADO   (United States)

^c Evicom   (United Kingdom)

Author keywords

Cost effectiveness; Granulocyte colony stimulating factor; Meta analysis; Non Hodgkin's lymphoma

Indexed keywords

ANTINEOPLASTIC AGENT; HEMOPOIETIC GROWTH FACTOR;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PREVENTION; CELL COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG COST; DRUG EFFECT; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; INCIDENCE; INFECTION; MAJOR CLINICAL STUDY; META ANALYSIS; NEUTROPENIA; NEUTROPHIL; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; UNITED KINGDOM;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS; HEMATOPOIETIC CELL GROWTH FACTORS; HUMANS; LYMPHOMA, NON-HODGKIN; MIDDLE AGED; NEUTROPENIA; RISK;

EID: 2342633841     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601708     Document Type: Article

References (14)

1. Aviles A, Diaz-Maqueo JC, Talavera A, Nambo MJ, Garcia EL (1994) Effect of granulocyte colony-stimulating factor in patients with diffuse large cell lymphoma treated with intensive chemotherapy. Leuk Lymphoma 15: 153-157
2. Bertini M, Freilone R, Vitolo U, Botto B, Ciotti R, Cinieri S, Di Nova A, Di Vito F, Levis A, Orsucci L, Pini M, Rota-Scalabrini D, Todeschini G, Resegotti L (1996) The treatment of elderly patients with aggressive non-Hodgkins lymphoma: feasibility and efficacy of an intensive multi-drug regimen. Leuk Lymphoma 22: 483-493
3. British National Formulation (2002) (number 43). London: British Medical Association & the Royal Pharmaceutical Society of Great Britian
4. Dranitsaris G, Altmayer C, Quirt I (1997) Cost-benefit analysis of prophylatic granulocyte colony-stimulating factor during CHOP antineoplastic therapy for non-Hodgkin's lymphoma. Pharmacoeconomics 11(6): 566-577
5. Fridik MA, Greil R, Hausmaninger H, Krieger O, Oppitz P, Stoger M, Klocker J, Neubauer M, Helm W, Pont J, Fazeny B, Hudec M, Simonitsch I, Radaszkiewicz T (1997) Randomised open label phase III trial of CEOP/IMVP-Dexa alternating chemotherapy and filgrastim versus CEOP/IMVP-Dexa alternating chemotherapy for aggressive non-Hodgkins lymphoma (NHL). A multi-center trial by the Austrian Working Group for Medical Tumour Therapy. Ann Hematol 75: 135-140
6. Gerhartz HH, Engelhard M, Meusers P, Brittinger G, Wilmanns W, Schlimok G, Mueller P, Huhn D, Musch R, Siegert W, Gerhartz D, Hartlapp JH, Thiel E, Huber C, Peschl C, Spann W, Emmerich B, Schadek C, Westerhausen M, Pees H-W, Radtke H, Engert A, Terhardt E, Schick H, Binder T, Fuchs R, Hasford J, Brandmaier R, Stern AC, Jones TC, Ehrlich HJ, Stein H, Parwaresch M, Tiemann M, Lennert K (1993) Randomized, double-blind, placebo-controlled, phase III study of recombinant human granulocyte-macrophage colony-stimulating factor as adjunct to induction treatment of high-grade malignant non-Hodgkin's lymphoma. Blood 82: 2329-2339
7. Gisselbrecht C, Haioun C, Lepage E, Bastion Y, Tilly H, Bosly A, Dupriex B, Marit G, Herbrecht R, Deconnick E, Marolleau JP, Yver A, Dabouz-Harrouche F, Coiffier B, Reyes F (1997) Placebo-controlled phase III study of lenograstim (glycosylated recombinant human granulocyte colony-stimulating factor in aggressive non-Hodgkins lymphoma: factors influencing chemotherapy administration. Leuk Lymphoma 25: 289-300
8. Office for National Statistics (ONS) (2001) Registrations, England 1999. Series MB1, no. 30. London: OBS
9. Office of Health Economics (1998) The Economic Aspects of Non-Hodgkin's Lymphoma. London: OHE
10. Pettengell R, Gurney H, Radford JA, Deakin DP, James R, Wilkinson PM, Kane K, Bentley J, Crowther D (1992) Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodkin's lymphoma. A randomised controlled trial. Blood 6: 1430-1436
11. Toner GC, Shapiro JD, Laidlaw CR, Rischin D, Millward MJ, Wolf M, Januszewicz H, Mitchell SV, Curran AC, Matthews JP, Bishop JF (1998) Low-dose versus standard-dose lenograstim prophylaxis after chemotherapy: a randomized, crossover comparison. J Clin Oncol 16(12): 3874-3879
12. Whitehead A, Whitehead J (1991) A general parametric approach to the meta-analysis of randomised clinical trials. Stat Med 10: 1665-1677
13. Zagonel V, Babare R, Merola MC, Talamini R, Lazzarini R, Tirelli U, Carbone A, Monfardini S (1994) Cost-benefit of granulocyte colony-stimulating factor administration in older patients with non-Hodgkin's lymphoma treated with combination chemotherapy. Ann Oncol 5(Suppl 2): S127-S132
14. Zinzani PL, Pavone E, Storti S, Moretti L, Fattori PP, Guardigni L, Falini B, Gobbi M, Gentilini P, Lauta VM, Bendandi M, Gherlinzoni F, Magagnoli M, Venturi S, Aitini E, Tabanelli M, Leone G, Liso V, Tura S (1997) Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin's lymphoma. Blood 89: 3974-3979